Ferrer, FerranPont, ÀngelsBlas, Rodolfo deBoladeras, AnnaGarin, O.Ventura, MontseZardoya, EvaDelgado, J.Condom, E.Merino Cabrera, EsperanzaMases, JoelCastells-Esteve, ManelGuix, InésSuárez-Novo, José FranciscoGonzalez, JavierAlmendros, SoniaGarcia, M.Berenguer, Miguel ÁngelGarcia, N.Stefanovic, M.Gutierrez, CristinaPicon, CristinaFerrer, MontserratGuedea Edo, Ferran2021-05-252021-05-252019-04-010167-8140https://hdl.handle.net/2445/177558Purpose or ObjectiveExtracranial stereotactic body radiation therapy (SBRT) allows delivering high doses per fraction with high accuracy to the prostatic gland in a low number of fractions.Dose escalation in normofractionaded radiation prostate cancer trials showed an increased toxicity.In order to evaluate the feasibility and toxicity of a regimen of a single dose hypofractionated prostate stereotactic boost a phase II study was undertaken. Self-reported quality of life (QOL) measures were also obtained in order to better define the possible deleterious effect of treatment.application/pdfengcc by-nc-nd (c) Elsevier Ireland Ltd, 2019http://creativecommons.org/licenses/by-nc-nd/3.0/es/RadioteràpiaCàncer de pròstataRadiotherapyProstate cancerinfo:eu-repo/semantics/conferenceObject2021-03-10info:eu-repo/semantics/openAccess